Clinical trial · Observational
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
NCT04127916CI-TRIAL-00044123unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study with retrospective data collection does not entail sample size calculation. The study will involve patients who received bendamustine + rituximab for relapsed/refractory mantle cell lymphoma and meet the inclusion/exclusion criteria at each participating study site. Considering the incidence of mantle cell lymphoma in Korea and the number of participating sites, the expected sample size is approximately 40.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bendamustine | Drug | Bendamustine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall response rate,
- timeFrame
- 2020.12.30
- description
- Overall response rate, including complete response and partial response
Secondary outcomes (5)
- measure
- Progression-free survival
- timeFrame
- 2020.12.30
- description
- The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
- measure
- Overall survival
- timeFrame
- 2020.12.30
- description
- The percentage of people in a study or treatment group still alive for a given period of time after diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Patients newly diagnosed with mantle cell lymphoma by a pathologist (based on the 2016 revision of the WHO classification) 1. mantle cell lymphoma 2. leukemic non-nodal mantle cell lymphoma 3. in situ mantle cell neoplasia 2. Age ≥ 19 years 3. Patients who received bendamustine + rituximab as initial therapy and patients who received bendamustine + rituximab for the treatment of relapsed/refractory condition are both included. Exclusion Criteria: * 1\. Patients whose clinical and pathological data are not available 2. Patients who were not treated with a combination of bendamustine and rituximab
References
Publications (0)
Data not yet available
No reference posted for this study.